Many efforts in lung cancer therapy have been focused on the development of COX-2 inhibitors because they can be used to suppress prostaglandinE2 (PGE2) formation from COX-2-catalyzed ω-6 arachidonic acid peroxidation [23]. This evidence concerns the gene PTGS2 and lung carcinoma.